Sanofi shares plunged after its experimental drug for the skin condition atopic dermatitis disappointed investors with a less ...

Sanofi (SNY) announced on Thursday that its experimental drug, Amlitelimab, met all primary and key secondary endpoints in a ...

A trial of Sanofi’s new eczema drug has disappointed investors hoping for a replacement for its blockbuster Dupixent, sending the French pharma group’s shares down more than 9 per cent on Thursday.

Shares in French drugmaker Sanofi fell more than 10% on Thursday, wiping nearly $13 billion off its market value, after ...

Sanofi stated that these positive results strengthen amlitelimab's potential as a treatment for atopic dermatitis. The company is currently conducting additional late-stage trials of the drug, which ...

Data from the late-stage trial of amlitelimab weren’t as strong as the results seen in Phase 2, adding to doubts about a drug ...

Amlitelimab has been billed by Sanofi as a successor to its Regeneron-partnered, $14.5 billion blockbuster Dupixent ...

Investing.com -- Sanofi (EPA:SASY) shares fell more than 9% on Thursday after the drugmaker reported results from a large trial of its experimental eczema treatment amlitelimab that showed weaker ...

Despite hitting its efficacy targets in the Phase III COAST-1 study, Sanofi’s amlitelimab remains “meaningfully inferior” to ...

Sanofi shares fall despite phase III success for eczema drug candidate, amlitelimab, showing strong efficacy and safety in ...

Amlitelimab showed efficacy in skin clearance compared to a placebo, but the results underwhelmed investors.

Kymera Therapeutics (KYMR) stock rises as RBC Capital Markets starts coverage with an Outperform recommendation, citing potential of lead drug KT-621. Read more here.